Oculis (NASDAQ:OCS – Get Free Report) had its price target upped by JPMorgan Chase & Co. from $38.00 to $42.00 in a report issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 45.10% from the company’s previous close.
A number of other equities research analysts have also recently commented on OCS. Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Stifel Nicolaus increased their target price on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Needham & Company LLC upped their price target on Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. Finally, HC Wainwright upped their price target on Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and a consensus target price of $45.71.
Get Our Latest Research Report on OCS
Oculis Stock Down 4.4%
Oculis (NASDAQ:OCS – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The company had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. As a group, equities research analysts forecast that Oculis will post -2.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new position in Oculis in the fourth quarter valued at about $80,000. Geode Capital Management LLC lifted its holdings in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the period. Finally, Koshinski Asset Management Inc. bought a new position in Oculis in the first quarter valued at about $238,000. Institutional investors own 22.30% of the company’s stock.
About Oculis
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Oculis
- Consumer-Driven Stocks Boost Buybacks, Including Visa’s $20B Plan
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
